Symptom · Long-haul vasomotor symptoms
Still flashing 10 years on. You're a third of women, not an outlier.
Most menopause writing assumes hot flashes last 'a few years' and quietly fade. The data says otherwise: a meaningful third of women keep having moderate-to-severe vasomotor symptoms more than a decade past their final period. If you're in that third and have been told you should be over this by now, here's what's actually true and what still works.
Educational · not medical advice
The Study of Women's Health Across the Nation (SWAN) followed thousands of women for over a decade and the headline number, that hot flashes last a median of 7.4 years, hides a much harder truth: about a third of women still have moderate-to-severe vasomotor symptoms more than 10 years past their final menstrual period. For Black women in the cohort the median duration was over 10 years; for women who started flashing in early perimenopause, longer still. If your hot flashes haven't followed the script, you are not unusual, you are the part of the data that doesn't get written about.
Why this is happening now
Long-haul vasomotor symptoms aren't a different condition, they're the same thermoregulatory misfire that started in peri, just continuing. What's different is the explanation you've been given (or not given) for why they've kept going.
- 01
The KNDy neurons don't always quiet down
Hot flashes are driven by hyperactive KNDy neurons in the hypothalamus. The original assumption was that they re-calibrate to low-estrogen baselines within a few years post-FMP. The newer evidence is that for a real subset of women they don't, or only partially do, and continue triggering thermoregulatory events for decades. The newer NK3 antagonist drugs (fezolinetant, and elinzanetant approved 2025) work directly on these neurons and don't 'expire' with menopause stage.
- 02
When you started predicts how long you'll go
Women whose vasomotor symptoms started in early perimenopause (FMP-7+ years) had the longest durations in the SWAN cohort, often 11+ years total. Women whose symptoms started post-FMP tended to have shorter courses. So if you started early, the long course isn't a personal failure, it's the population pattern.
- 03
Race, BMI, and stress all shift the curve
The SWAN study found Black women had a median total duration of over 10 years, the longest of any group studied. Higher BMI, smoking, depressive symptoms, and high perceived stress were all independently associated with longer durations. None of these are about willpower. They're about which biology you're working with.
- 04
Sleep destruction compounds the problem
A decade of fragmented sleep from night sweats does its own damage, mood, cognition, cardiovascular risk, blood sugar regulation. The 'just live with it' framing underestimates how much harm comes from the downstream sleep loss, not the flashes themselves.
- 05
'You should be over this' is cultural, not clinical
There's no clinical guideline that says vasomotor symptoms are supposed to stop by year five, or that treatment becomes inappropriate at any specific time post-FMP. The current consensus from North American Menopause Society (NAMS), BMS and IMS is that severity and impact, not menopause stage, drive treatment decisions.
What people actually find helps (in long-haul)
Almost every option that works in early menopause also works in long-haul. The conversations are sometimes harder to start, the answers aren't different.
Re-open the HRT conversation, even if you said no before
Many women in long-haul cases were told 'no' or 'too late' for HRT a decade ago, often based on the over-extrapolated 2002 Women’s Health Initiative (WHI) headlines. The current consensus has moved substantially: for women without contraindications who start HRT within ten years of their final menstrual period (FMP) and are still benefiting, continuing is reasonable with annual review. Starting later than that is more nuanced but not categorically off the table. A menopause-trained specialist can lay out your specific risk picture honestly.
Fezolinetant (NK3 antagonist), the newer non-hormonal lever
Approved in 2023, fezolinetant directly targets the KNDy neurons driving hot flashes. It works regardless of menopause stage, time since FMP, or whether you've tried HRT before. Trial data shows around a 60% reduction in moderate-to-severe vasomotor symptoms. Liver monitoring is required in the first months. A real option for long-haul cases that aren't suitable for HRT. Elinzanetant (Lynkuet, Bayer) was approved in 2025 as a second NK3 antagonist — dual-acting on the same pathway, with added benefit on sleep and mood disturbance, and no liver-monitoring requirement.
Other non-hormonal prescriptions still work
Low-dose paroxetine (the only FDA-approved selective serotonin reuptake inhibitor (SSRI) for vasomotor symptoms (VMS)), venlafaxine, gabapentin and oxybutynin all have randomized-trial evidence and don't lose effect with time post-FMP. None work as well as HRT, but all outperform doing nothing. Worth a conversation if you've ruled out hormones.
CBT-Meno, evidence holds in long-haul cases
The cognitive behavioural therapy protocol designed for menopause has good trial evidence for reducing how much hot flashes bother you, even when frequency stays the same. It works at any stage post-FMP. Ask your doctor for a referral or look for trained therapists through the British Menopause Society directory.
3 more practices, plus podcasts, books and research, live in Go deeper below.
03When to get help nowWhen it's not 'just' long-haul flashes
Emergency red flags, same-week signs, and where to find a menopause-trained practitioner.
When it's not 'just' long-haul flashes
4 more signs it needs a doctor this week
Sudden new onset of severe flashes after years of quiet
If your VMS had quieted and then came back loudly years later, that's worth investigating, sometimes a medication change, thyroid, occasionally other causes. Not always menopause coming back.
Drenching night sweats with weight loss, fever, or swollen glands
This combination is rarely menopause alone and warrants prompt investigation. Don't wait it out. See a doctor within a week.
Flashes plus chest pain, breathlessness, or dizziness
Cardiac symptoms in midlife and older women are routinely misread as menopause. If a flash comes with crushing chest pressure, jaw pain, or one-sided arm pain, call emergency services.
You've been refused care because of your age
Age alone isn't a contraindication to treating long-haul VMS. If you've been told you're 'too old for hormones' or 'past the point of treatment', that's usually outdated guidance. A menopause-trained specialist can give you the actual risk-benefit picture for you.
Go deeper
One place for everything else.
Practices to try this week, voices worth hearing, books worth your bedside table, rooms where members are talking, the candid tips Nila would share over a cup of tea, and the research the editorial team is watching.
Frequency and severity, separately
Three mild flashes is not the same as one that takes you out. Tracking both gives you the cleanest before/after when you change anything.
Sleep quality, not just hours
Night sweats fragment deep sleep without always waking you. A wearable that tracks wake events makes the pattern visible.
How much it's actually costing you
Mood, work, relationships, exercise. Long-haul VMS often quietly shapes everything. Naming the cost is what often re-opens the treatment conversation.
Cardiovascular markers, annually
Severe long-duration VMS are independently associated with higher cardiovascular risk. Lipids, BP, fasting glucose deserve attention regardless.
Related